The individualized formular administration of tacrolimus after kidney transplantation based on the CYP3A5 and MDR1 gene polymorphism
10.3760/cma.j.issn.0254-1785.2018.01.002
- VernacularTitle:基于CYP3A5、MDR1基因多态性的公式化用药对肾移植术后早期他克莫司用药的指导意义
- Author:
Dongfu LIU
1
;
Yue MA
;
Shengqiang YU
;
Jiantao WANG
;
Fei Zheng SHAN
;
Chengjun ZHANG
;
Fengchun WAN
;
Zhenli GAO
Author Information
1. 青岛大学附属烟台毓璜顶医院器官移植科
- Keywords:
Kidney transplantation;
Tacrolimus;
CYP3A5;
MDR1;
Individualized formula
- From:
Chinese Journal of Organ Transplantation
2018;39(1):7-11
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the feasibility and clinical significance of individualized formular administration of tacrolimus after renal transplantation based on the CYP3A5 and MDR1 gene polymorphism.Methods Total 129 renal transplantation recipients from Oct.1,2015 to July 30,2016 were included in this study and divided into 2 groups.In experimental group,tacrolimus was administrated by the individualized formula based on CYP3A5 and MDR1 gene polymorphism;in control group,tacrolimus was administrated by doctors' experience based on patient's body weight.The blood trough level of tacrolimus was determined 3 days after administration.The first blood trough level of tacrolimus,plasma creatinine level,acute rejection rate,and necessity for dialysis were compared between two groups.Results The first blood trough levels of tacrolimus in experimental and control groups were 9.24 ± 2.32 and 9.39 ± 3.47μg/L respectively (P＞0.05).The tacrolimus levels of 7 cases in experimental group and 18 cases in control group were not in normal range (P＜0.05).The plasma creatinine level at day 7 after surgery was 157.36 ± 110.55 μg/L in experimental group,and 174.01 ± 130.68μg/L in control group (P＞0.05).Acute rejection was found in both two groups:2 in experimental group and 5 in control group (P ＞ 0.05).There was significant difference in necessity for dialysis between two groups:4 in experimental group and 10 in control group (P＜0.05).Conclusion The individualized formular administration of tacrolimus based on the CYP3A5 and MDR1 gene polymorphism is more feasible and reasonable than experimental administration,which is more easier to come to an appropriate blood level and would benefit the early recovery of renal function.
